HEMATOLOGY

Despite the success of implementing maintenance therapy in other leukemias, the key challenge with administering maintenance therapy in acute myeloid leukemia has been identifying an effective drug.

Investigators are looking into newer ways of using hypomethylating agents to treat patients with low-risk and high-risk myelodysplastic syndrome.

In an interview with Targeted Oncology, Annette S. Kim, MD, PhD, discussed the updates to the NCCN guidelines on myeloid/lymphoid neoplasms with eosinophilia, along with how to bring new pathology strategies for these disease into clinical practice.

Michael Bishop, MD, leads the discussion on approaching the first-line management of acute GVHD and the importance of early intervention for patients at risk for the disease.

Expert hematologist-oncologists provide insight on major risk factors for GVHD and associated challenges for treatment.

Three medical oncologists from Florida Cancer Specialists are co-authors on a new integrated safety analysis of umbralisib, used to treat lymphoid malignancies.

Dr John DiPersio discusses an early intervention approach to the management of chronic and acute GVHD.

John DiPersio, MD, PhD, and Michael Bishop, MD, define acute and chronic graft-vs-host disease (GVHD).

In an interview with Targeted Oncology™: Jeffrey Miller, MD, discussed the use of NK cell destruction to boost IL-15 efficacy in refractory tumors.

Moshe Levy, MD discusses the ongoing phase 3b study of asciminib in patients with chronic myeloid leukemia in chronic phase.

In an interview with Targeted Oncology during the SOHO Annual Meeting, Elisabetta Abruzzese, MD, provided key recommendations for managing pregnancy and chronic myeloid leukemia.

The FDA has approved ruxolitinib for the treatment of chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

A biologics license application has been submitted to the FDA for betibeglogene autoemcel gene therapy for the treatment of adult, adolescent, and pediatric patients with B-thalassemia who require regular blood cell transfusions.

During a Targeted Oncology Case-Base Roundtable event, Yi-Bin A. Chen, MD, discussed options for treating acute and chronic graft versus host disease.

Corey S. Cutler, MD, MPH, FRCPC, discusses the trial of belumosudil in patients with chronic graft-vs-host disease.

Rituximab with bendamustine lead to superior outcomes compared with than 2 other popular triplet therapies in patients with treatment-naïve Waldenström macroglobulinemia.

For patients with low-risk myelodysplastic syndrome, standardized treatment options are not readily available and dependent on the patient’s specific conditions.

Nelson J. Chao, MD, discusses a shift at Duke Cancer Institute from in-office care to home care in patients undergoing hematopoietic stem cell transplantation for hematologic malignancies.

Experts who treat chronic graft-versus-host disease have not only learned to understand the pathophysiology of the disease but are also understanding how to implement new treatment modalities.

Zanubrutinib has been approved by the FDA to treat adult patients with Waldenström macroglobulinemia.

The FDA has accepted the supplemental biologics license application for abatacept and granted it priority review for the prevention of moderate to severe acute graft versus host disease in patients 6 years of age and older receiving unrelated donor hematopoietic stem cell transplantation.

During a Targeted Oncology Case-Based Roundtable event, Nelson Jen An Chao, MD of Duke University School of Medicine discussed a 48-year-old patient with graft-vesus-host disease.

As more chimeric antigen receptors undergo clinical development for the treatment of hematologic malignancies, their approval for use in a wider array of malignancies is inevitable.

During a Targeted Oncology Case-Based Roundtable event, Nelson Jen An Chao, MD, a discussed the case of a young patient with acute graft-versus-host disease.

Stephanie Lee, MD, MPH, discusses the study of ruxolitinib plus best available therapy as a second-line treatment for patients with chronic graft-versus-host disease.

Fast track designation has been granted by the FDA to eryaspase for the treatment of patients with acute lymphocytic leukemia who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase.

Marcin Kortylewski, PhD, discusses the need for additional strategies for the treatment of acute myeloid leukemia.

The FDA has granted breakthrough therapy designation to the combination of venetoclax and azacitidine for the treatment of adult patients with previously untreated intermediate-, high- and very high-risk myelodysplastic syndromes.